Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate ...

CIRRUS-HCM is a multi-part, open-label trial of EDG-7500 in individuals with HCM. In September 2024, the Company announced positive top-line data from Part A of the trial showing that a single ...

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

As previously reported yesterday, Scotiabank downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a price target of ...

Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

This time around, I want to focus on the release of initial data from the phase 2 CIRRUS-HCM study, which uses another drug known as EDG-7500 for the treatment of patients with hypertrophic ...

– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated ...

EWTX is evaluating EDG-7500, a novel oral, selective, cardiac sarcomere modulator with a unique mechanism of action, in the ongoing phase II CIRRUS-HCM study. The latest data readout is from Part ...